Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of CDP323 in relapsing multiple sclerosis
2006-002204-33Phase 2Completed
- Sponsor
- UCB
- Start
- Feb 2007
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing CDP323 500 mg twice daily with Placebo (2 arms). Primary endpoints: Primary efficacy variable (MRI-based MS-related imaging parameters) and Safety and tolerability. Started Feb 2007; status: completed.
02
Drugs
zaurategrast
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2006-002204-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002204-33.